PACAP inhibits β-cell mass expansion in a mouse model of type II diabetes: Persistent suppressive effects on islet density

Frontiers in Endocrinology

Volumn 4, Issue MAR, 2013, Pages

  Inoue, Hiroaki ^a   Shintani, Norihito ^a   Sakurai, Yusuke ^a,b   Higashi, Shintaro ^a,b   Hayata Takano, Atsuko ^a,c,d,e,f   Baba, Akemichi ^a,g   Hashimoto, Hitoshi ^a,c,d,e,f  

^a OSAKA UNIVERSITY   (Japan)

^b JAPAN SOCIETY FOR THE PROMOTION OF SCIENCE   (Japan)

^c KANAZAWA UNIVERSITY   (Japan)

^d HAMAMATSU UNIVERSITY SCHOOL OF MEDICINE   (Japan)

^e CHIBA UNIVERSITY   (Japan)

^f UNIVERSITY OF FUKUI   (Japan)

^g HYOGO COLLEGE OF MEDICINE   (Japan)

Author keywords

Cells; High fat diet; Islet neogenesis; Kkay mice; Pituitary adenylate cyclase activating polypeptide; Type 2 diabetes

Indexed keywords

HYPOPHYSIS ADENYLATE CYCLASE ACTIVATING POLYPEPTIDE;

ANIMAL EXPERIMENT; ANIMAL MODEL; ANIMAL TISSUE; ARTICLE; DENSITY; ENZYME LINKED IMMUNOSORBENT ASSAY; FEMALE; GLUCOSE TOLERANCE TEST; GRANULATION TISSUE; HISTOCHEMISTRY; ISLET DENSITY; LIPID DIET; MALE; MORPHOMETRICS; MOUSE; NON INSULIN DEPENDENT DIABETES MELLITUS; NONHUMAN; OBESITY; PANCREAS ISLET ALPHA CELL; PANCREAS ISLET BETA CELL; PHENOTYPE; PROTEIN EXPRESSION;

EID: 84884407780     PISSN: None     EISSN: 16642392     Source Type: Journal    
DOI: 10.3389/fendo.2013.00027     Document Type: Article

References (24)

1. Ahrén, B. (2008). Role of pituitary adenylate cyclase-activating polypeptide in the pancreatic endocrine system. Ann. N. Y. Acad. Sci. 1144, 28-35.
2. Ahrén, B. (2009). Islet G protein-coupled receptors as potential targets for treatment of type 2 diabetes. Nat. Rev. Drug. Discov. 8, 369-385.
3. Bonner-Weir, S., Toschi, E., Inada, A., Reitz, P., Fonseca, S. Y., Aye, T., et al. (2004). The pancreatic ductal epithelium serves as a potential pool of progenitor cells. Pediatr. Diabetes 5, 16-22.
4. Brennand, K., and Melton, D. (2009). Slow and steady is the key to beta-cell replication. J. Cell Mol. Med. 13, 472-487.
5. Butler, A. E., Janson, J., Bonner-Weir, S., Ritzel, R., Rizza, R. A., and Butler, P. C. (2003). Beta-cell deficit and increased beta-cell apoptosis in humans with type 2 diabetes. Diabetes 52, 102-110.
6. Chapter, M. C., White, C. M., DeRidder, A., Chadwick, W., Martin, B., and Maudsley, S. (2010). Chemical modification of class II G protein-coupled receptor ligands: frontiers in the development of peptide analogs as neuroendocrine pharmacological therapies. Pharmacol. Ther. 125, 39-54.
7. Dalle, S., Ravier, M. A., and Bertrand, G. (2011). Emerging roles for β-arrestin-1 in the control of the pancreatic β-cell function and mass: new therapeutic strategies and consequences for drug screening. Cell. Signal. 23, 522-528.
8. Fabricius, D., Karacay, B., Shutt, D., Leverich, W., Schafer, B., Takle, E., et al. (2011). Characterization of intestinal and pancreatic dysfunction in VPAC1-null mutant mouse. Pancreas 40, 861-871.
9. Hanley, S. (2009). Pancreatic β-cell mass as a pharmacologic target in diabetes. Mcgill. J. Med. 12, 51-60.
10. Hashimoto, H., Shintani, N., Tanaka, K., Mori, W., Hirose, M., Matsuda, T., et al. (2001). Altered psychomotor behaviors in mice lacking pituitary adenylate cyclase-activating polypeptide (PACAP). Proc. Natl. Acad. Sci. U.S.A. 98, 13355-13360.
11. Holst, J. J. (2006). Glucagon-like peptide-1: from extract to agent. The Claude Bernard lecture, 2005. Diabetologia 49, 253-260.
12. Iwatsuka, H., Shino, A., and Suzuoki, Z. (1970). General survey of diabetic features of yellow KK mice. Endocrinol. Jpn. 17, 23-35.
13. Martin, B., Shin, Y. K., White, C. M., Ji, S., Kim, W., Carlson, O. D., et al. (2010). Vasoactive intestinal peptide-null mice demonstrate enhanced sweet taste preference, dysglycemia, and reduced taste bud leptin receptor expression. Diabetes 59, 1143-1152.
14. Nakata, M., Shintani, N., Hashimoto, H., Baba, A., and Yada, T. (2010). Intra-islet PACAP protects pancreatic β-cells against glucotoxicity and lipotoxicity. J. Mol. Neurosci. 42, 404-410.
15. Sakurai, Y., Inoue, H., Shintani, N., Arimori, A., Hamagami, K., Hayata-Takano, A., et al. (2012). Compensatory recovery of blood glucose levels in KKAy mice fed a high-fat diet; insulin-sparing effects of PACAP overexpression in β cells. J. Mol. Neurosci. 48, 647-653.
16. Sakurai, Y., Shintani, N., Hayata, A., Hashimoto, H., and Baba, A. (2011). Trophic effects of PACAP on pancreatic islets: a mini-review. J. Mol. Neurosci. 43, 3-7.
17. Srinivasan, K., and Ramarao, P. (2007). Animal models in type 2 diabetes research: an overview. Indian J. Med. Res. 125, 451-472.
18. Tomimoto, S., Hashimoto, H., Shintani, N., Yamamoto, K., Kawabata, Y., Hamagami, K., et al. (2004). Overexpression of pituitary adenylate cyclase-activating polypeptide in islets inhibits hyperinsulinemia and islet hyperplasia in agouti yellow mice. J. Pharmacol. Exp. Ther. 309, 796-803.
19. Tomimoto, S., Ojika, T., Shintani, N., Hashimoto, H., Hamagami, K., Ikeda, K., et al. (2008). Markedly reduced white adipose tissue and increased insulin sensitivity in adcyap1-deficient mice. J. Pharmacol. Sci. 107, 41-48.
20. Vaithilingam, V., Sundaram, G., and Tuch, B. E. (2008). Islet cell transplantation. Curr. Opin. Organ Transplant 13, 633-638.
21. Vaudry, D., Falluel-Morel, A., Bourgault, S., Basille, M., Burel, D., Wurtz, O., et al. (2009). Pituitary adenylate cyclase-activating polypeptide and its receptors: 20 years after the discovery. Pharmacol. Rev. 61, 283-357.
22. Verspohl, E. J. (2009). Novel therapeutics for type 2 diabetes: incretin hormone mimetics (glucagon-like peptide-1 receptor agonists) and dipeptidyl peptidase-4 inhibitors. Pharmacol. Ther. 124, 113-138.
23. Yada, T., Sakurada, M., Ihida, K., Nakata, M., Murata, F., Arimura, A., et al. (1994). Pituitary adenylate cyclase activating polypeptide is an extraordinarily potent intra-pancreatic regulator of insulin secretion from islet beta-cells. J. Biol. Chem. 269, 1290-1293.
24. Yamamoto, K., Hashimoto, H., Tomimoto, S., Shintani, N., Miyazaki, J., Tashiro, F., et al. (2003). Overexpression of PACAP in transgenic mouse pancreatic beta-cells enhances insulin secretion and ameliorates streptozotocin-induced diabetes. Diabetes 52, 1155-1162.